Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Significance: Alzheimer’s disease (AD) is a devastating disease that results in the progressive cognitive deficits of elderly and has become one of major social and economic burdens worldwide. There is no effective drug or therapy to prevent or halt the progressive cognitive dysfunctions due to the complex mechanisms such as accumulation of amyloid-β (Aβ), increase in oxidative stress, and formation of neurofibrillary tangle that drive the development of the disease. We found here that Edaravone, a drug that has been used for ischemic stroke, is able to prevent and treat AD by targeting multiple pathways of AD pathogenesis and rescuing the cognitive deficits of a mouse model of AD. Our study suggests Edaravone is a promising drug candidate for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“The intraneuronal NFT caused by hyperphosphorylation of Tau protein is another hallmark of AD (33) and consistently correlated with the cognitive dysfunctions in patients (34, 35).”
BackgroundAlzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2007) · Advances in Behavioral Biology · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,468
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“Despite significant progress that has been made toward understanding the pathogenesis of AD in recent years, no efficient disease-modifying therapeutics are available for the management of AD (4).”
BackgroundKalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 2×
“Proc Natl Acad Sci USA 112(8):E881–E890.”
BackgroundHuang, X., Atwood, C. S., Hartshorn, M. A., Multhaup, G., Goldstein, L. E., Scarpa, R. C., Cuajungco, M. P., Gray, D. N., Lim, J., Moir, R. D., et al. (1999) · Biochemistry · doi:10.1021/bi990438f · Cited by 1,107
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 2×
“Cold Spring Harb Perspect Med 2(7):a006338.”
BackgroundDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo
Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00259-9 · Cited by 509 · cited 2×
“Noble W, et al. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo.”
BackgroundInhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442 · cited 11×
“Ly PT, et al. (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.”
BackgroundInfluentialMolecular basis for amyloid-β polymorphism
Colletier, J.-P., Laganowsky, A., Landau, M., Zhao, M., Soriaga, A. B., Goldschmidt, L., Flot, D., Cascio, D., Sawaya, M. R., & Eisenberg, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112600108 · Cited by 402
Neuroprotective Effects of Edaravone: a Novel Free Radical Scavenger in Cerebrovascular Injury
Yoshida, H., Yanai, H., Namiki, Y., Fukatsu-Sasaki, K., Furutani, N., & Tada, N. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00009.x · Cited by 399 · cited 2×
“In the present study, we took such an approach and investigated the potential therapeutic effect of Edaravone, an oxygen radical scavenger that is currently used for the treatment of acute ischemic stroke (13, 14).”
BackgroundWang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Teplow, D. B., & Pasinetti, G. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0364-08.2008 · Cited by 361 · cited 1×
“Previous studies suggested that several natural antioxidants such as curcumin and grape-derived polyphenolics can inhibit aggregation of Aβ (20, 21).”
BackgroundEpigenetics, oxidative stress, and Alzheimer disease
Zawia, N. H., Lahiri, D. K., & Cardozo-Pelaez, F. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.006 · Cited by 337
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
The future of Alzheimer's disease: The next 10 years
Hampel, H., Prvulovic, D., Teipel, S., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 235
The Novel Antioxidant Edaravone: From Bench to Bedside
Watanabe, T., Tahara, M., & Todo, S. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1527-3466.2008.00041.x · Cited by 227 · cited 2×
“In addition, the lipophilic nature of both phenyl and methyl groups of Edaravone render its excellent property of penetrating BBB (24) for its interaction with Aβ in the brain.”
BackgroundFlaherty, D. B., Soria, J., Tomasiewicz, H. G., & Wood, J. G. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20001101)62:3<463::aid-jnr16>3.0.co;2-7 · Cited by 198
Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients
Patton, R. L., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Van Vickle, G. D., Luehrs, D. C., Kuo, Y.-M., Lopez, J., Brune, D., Ferrer, I., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192
Chami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168 · cited 2×
“Guglielmotto M, et al. (2011) Amyloid-β₄₂ activates the expression of BACE1 through the JNK pathway.”
BackgroundWen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., Lau, L.-F., Yu, W. H., & Duff, K. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5245-07.2008 · Cited by 145
cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex
Carlyle, B. C., Nairn, A. C., Wang, M., Yang, Y., Jin, L. E., Simen, A. A., Ramos, B. P., Bordner, K. A., Craft, G. E., Davies, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322360111 · Cited by 139 · cited 12×
“Ly PT, et al. (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.”
BackgroundInfluentialOxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors
Guglielmotto (2010) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2010 · Cited by 134
The amyloid cascade hypothesis
Korczyn, A. D. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.11.008 · Cited by 132 · cited 1×
“Accumulating evidence indicates that amyloid-β (Aβ) and its oligomers play central roles in the pathogenesis of AD (3).”
BackgroundHan, B. H., Zhou, M.-L., Johnson, A. W., Singh, I., Liao, F., Vellimana, A. K., Nelson, J. W., Milner, E., Cirrito, J. R., Basak, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414930112 · Cited by 131 · cited 12×
“These findings suggest that Edaravone would also be a promising drug candidate for CAA.”
BackgroundInfluentialAmyloid-β Production: Major Link Between Oxidative Stress and BACE1
Tamagno, E., Guglielmotto, M., Monteleone, D., & Tabaton, M. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9283-6 · Cited by 127
Edaravone for acute ischaemic stroke
Feng, S., Yang, Q., Liu, M., Li, W., Yuan, W., Zhang, S., Wu, B., & Li, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007230.pub2 · Cited by 126 · cited 1×
“In the present study, we took such an approach and investigated the potential therapeutic effect of Edaravone, an oxygen radical scavenger that is currently used for the treatment of acute ischemic stroke (13, 14).”
BackgroundSelf-citationNFκB-dependent Control of BACE1 Promoter Transactivation by Aβ42
Buggia-Prevot, V., Sevalle, J., Rossner, S., & Checler, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706579200 · Cited by 125
(2012) · doi:10.1038/nrneurol.2012.118 · Cited by 122 · cited 2×
“In recent years, a number of drug candidates targeting Aβ through immunotherapy or using secretase inhibitors have proceeded to clinical trials but all failed to improve cognitive functions in patients (5).”
BackgroundSelf-citationChami, L., Buggia-Prévot, V., Duplan, E., Delprete, D., Chami, M., Peyron, J.-F., & Checler, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333054 · Cited by 120
Longitudinal stability of CSF tau levels in Alzheimer patients
Sunderland, T., Wolozin, B. L., Galasko, D., Levy, J., Dukoff, R. A., Bahro, M., Lasser, R. A., Motter, R. N., Lehtimäki, T. J., & Seubert, P. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00143-2 · Cited by 119 · cited 1×
“The intraneuronal NFT caused by hyperphosphorylation of Tau protein is another hallmark of AD (33) and consistently correlated with the cognitive dysfunctions in patients (34, 35).”
BackgroundWang, Y.-J., Wang, X., Lu, J.-J., Li, Q.-X., Gao, C.-Y., Liu, X.-H., Sun, Y., Yang, M., Lim, Y., Evin, G., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2733-10.2011 · Cited by 100
Self-citationLessons from immunotherapy for Alzheimer disease
Wang, Y. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.44 · Cited by 87 · cited 2×
“Therefore, we proposed that it is critical to discover novel drugs, which target multiple key pathways in the pathogenesis of AD, to improve or halt the progression of the disease (6).”
BackgroundSelf-citationOxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease
UTSA Neurosciences Institute and Department of Biology, C. O. S., Perry, G., Lee, H.-G., Lee, H. P., Zhu, X., Smith, M. A., Department of Pathology, C. W. R. U., Rolston, R. K., Geisinger Medical Center, D., Marlatt, M. W., et al. (2010) · International Journal of Biomedical Science · doi:10.59566/ijbs.2010.6225 · Cited by 81 · cited 3×
“It is well recognized that the formation of NFT is a down-stream event of Aβ toxicity that is caused by Tau hyperphosphorylation triggered by Aβ-induced activation of several kinases such as Cdk5 (36), GSK3β (37) and PKA (37).”
BackgroundAmyloid-β 42 Activates the Expression of BACE1 Through the JNK Pathway
Guglielmotto, M., Monteleone, D., Giliberto, L., Fornaro, M., Borghi, R., Tamagno, E., & Tabaton, M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110884 · Cited by 63
Initiative, F. T. A. D. N., Han, S. D., Gruhl, J., Beckett, L., Dodge, H. H., Stricker, N. H., Farias, S., & Mungas, D. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9177-0 · Cited by 62
Cerebral amyloidal angiopathy—A disease with implications for neurology and psychiatry
Gahr, M., Nowak, D. A., Connemann, B. J., & Schönfeldt‐Lecuona, C. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.052 · Cited by 50 · cited 1×
“CAA is a common disorder caused by the deposition of Aβ in the vessel wall of small arterial vessels of the brain, leading to cerebral hemorrhage, ischemia, and infarction (39).”
BackgroundEdaravone Ameliorates Oxidative Damage Associated with Aβ25-35 Treatment in PC12 Cells
Zhang, G., Zhang, W., Du, Y., Li, Y., Sun, H. B., Zhang, R., Liu, E., Bu, N., Wu, H., Zhang, L., et al. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-9973-z · Cited by 26 · cited 1×
“Previous study found that Edaravone was able to attenuate Aβ-induced oxidative stress and neurotoxicity (18, 19).”
BackgroundEdaravone for acute ischaemic stroke
Feng, S., Yang, Q., Liu, M., Li, W., Zhang, S., Wu, B., & Yuan, W. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007230 · Cited by 16
Cited by
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02400-6 · Cited by 520
Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress
Ahmadinejad, F., Geir Møller, S., Hashemzadeh-Chaleshtori, M., Bidkhori, G., & Jami, M.-S. (2017) · Antioxidants · doi:10.3390/antiox6030051 · Cited by 297
Pan, R.-Y., Ma, J., Kong, X.-X., Wang, X.-F., Li, S.-S., Qi, X.-L., Yan, Y.-H., Cheng, J., Liu, Q., Jin, W., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau6328 · Cited by 288
Fan, S., Zheng, Y., Liu, X., Fang, W., Chen, X., Liao, W., Jing, X., Lei, M., Tao, E., Ma, Q., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1461955 · Cited by 258
Self-citationTargeting neuroinflammation in Alzheimer’s disease
Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86958 · Cited by 255
Metadata
- Authors
- Jiao, S.-S., Yao, X.-Q., Liu, Y.-H., Wang, Q.-H., Zeng, F., Lu, J.-J., Liu, J., Zhu, C., Shen, L.-L., Liu, C.-H., Wang, Y.-R., Zeng, G.-H., Parikh, A., Chen, J., Liang, C.-R., Xiang, Y., Bu, X.-L., Deng, J., Li, J., Xu, J., Zeng, Y.-Q., Xu, X., Xu, H.-W., Zhong, J.-H., Zhou, H.-D., Zhou, X.-F., & Wang, Y.-J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-04-06
- Volume
- 112
- Issue
- 16
- Pages
- 5225-5230
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2171818152
- Cited by
- 174
- References
- 44
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.